Assembly Biosciences, Inc. (NASDAQ:ASMB) Short Interest Up 25.5% in February

Assembly Biosciences, Inc. (NASDAQ:ASMB) saw a large increase in short interest during the month of February. As of February 15th, there was short interest totalling 17,200 shares, an increase of 25.5% from the January 31st total of 13,700 shares. Approximately 0.5% of the shares of the company are sold short. Based on an average daily trading volume, of 33,700 shares, the days-to-cover ratio is presently 0.5 days.

Analyst Ratings Changes

Separately, HC Wainwright reiterated a “neutral” rating on shares of Assembly Biosciences in a research report on Friday, December 27th.

Insider Transactions at Assembly Biosciences

In related news, Director Michael Houghton acquired 3,202 shares of the business’s stock in a transaction on Monday, December 30th. The stock was purchased at an average cost of $15.61 per share, for a total transaction of $49,983.22. Following the completion of the transaction, the director now directly owns 3,202 shares of the company’s stock, valued at approximately $49,983.22. The trade was a ∞ increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. 5.10% of the stock is currently owned by corporate insiders.

Institutional Trading of Assembly Biosciences

A number of institutional investors have recently modified their holdings of the stock. Gilead Sciences Inc. bought a new position in shares of Assembly Biosciences in the fourth quarter worth $34,865,000. Renaissance Technologies LLC raised its position in shares of Assembly Biosciences by 44.3% in the 4th quarter. Renaissance Technologies LLC now owns 94,711 shares of the biopharmaceutical company’s stock valued at $1,495,000 after buying an additional 29,087 shares in the last quarter. Peapod Lane Capital LLC bought a new stake in shares of Assembly Biosciences during the 4th quarter worth approximately $994,000. B Group Inc. acquired a new stake in shares of Assembly Biosciences during the 4th quarter worth approximately $799,000. Finally, Monimus Capital Management LP bought a new position in Assembly Biosciences in the fourth quarter valued at approximately $664,000. 19.92% of the stock is currently owned by institutional investors.

Assembly Biosciences Stock Down 2.3 %

Shares of ASMB opened at $11.95 on Wednesday. The firm’s 50 day moving average is $14.28 and its 200-day moving average is $15.55. Assembly Biosciences has a 12 month low of $11.27 and a 12 month high of $19.93.

About Assembly Biosciences

Assembly Biosciences, Inc, a biotechnology company, develops therapeutic candidates for the treatment of viral diseases. It develops ABI-5366, a long-acting herpes simplex virus (HSV) helicase-primase inhibitor that is in Phase 1a/1b clinical trial to treat recurrent genital herpes; ABI-1179, which is in Phase 1a/1b clinical trial for the treatment of recurrent genital herpes; and ABI-6250, a small molecule orally bioavailable hepatitis delta virus entry inhibitor that is in Phase 1a clinical trial.